摘要
目的 评价双磷酸盐用于原发性骨质疏松症治疗上的临床疗效。方法 选取本院在2019年1月-2020年6月收治的原发性骨质疏松症患者共80例作为主要对象,以随机数字表法的原则分组,各40例。对照组通过口服钙尔奇治疗,观察组在对照组基础上增加阿仑膦酸钠+唑来膦酸治疗,比较两种用药方案的治疗效果。结果 相比于对照组,观察组的治疗总有效率更高,差异显著(P<0.05);两组治疗后患者的腰椎功能较治疗前相比均明显改善,观察组治疗后患者的腰椎功能明显优于对照组,两组比较差异显著(P<0.05);两组治疗后患者的临床症状评分均小于治疗前,观察组小于对照组,差异显著(P>0.05);经比较不良反应的发生情况,结果提示观察组和对照组患者在治疗期间的不良反应发生率相比并无明显差异(P>0.05)。结论 采用阿仑膦酸钠+唑来膦酸治疗原发性骨质疏松症兼具有效性和安全性,有利于改善患者的腰椎功能,故具备临床借鉴意义和推广价值。
Objective To evaluate the clinical effect of bisphosphonates on primary osteoporosis.Methods A total of 80 patients with primary osteoporosis admitted to our hospital from January 2019 to June 2020 were selected as the main subjects,and they were divided into random number table method,with 40 patients in each group.The control group was treated with oral calcitrine,and the observation group was treated with alendronate+zoledronic acid on the basis of the control group,and the therapeutic effects of the two drug regimens were compared.Results Compared with the control group,the total effective rate of observation group was significantly higher(P<0.05);After treatment,the lumbar spine function of patients in both groups was significantly improved compared with that before treatment,and the lumbar spine function of patients in the observation group was significantly better than that in the control group,with significant difference between the two groups(P<0.05);The clinical symptom scores of the patients in the two groups after treatment were lower than those before the treatment,and the observation group was lower than the control group,and the difference was significant;By comparing the occurrence of adverse reactions,the results showed that there was no significant difference in the incidence of adverse reactions between the observation group and the control group during treatment(P>0.05).Conclusion Alendronate+zoledronic acid in the treatment of primary osteoporosis has both effectiveness and safety,which is beneficial to improve the lumbar spine function of patients,so it has clinical reference and promotion value.
作者
郭吉璇
GUO Jixuan(Endocrinology Department,Shantou Chaonan Minsheng Hospital,Shantou,Guangdong 515100)
出处
《智慧健康》
2023年第7期79-82,共4页
Smart Healthcare